Analysis of the Effect of Ambroxol Nebulization Inhalation as an Auxiliary Treatment for Pneumonia in Clinical Medicine
Vol. 28 (2026): 2026 2nd International Conference on Agricultural Sciences, Economics, Biomedical and Environmental Sciences (SEMBE 2026)
Received: 2026-07-18
Accepted: 2026-07-18
Published: 2026-07-18
Abstract
This study explores the clinical efficacy of inhaled ambroxol hydrochloride in treating adult bacterial pneumonia, specifically analyzing its impact on pulmonary function and serum inflammatory factors. A total of 120 patients with bacterial pneumonia, admitted between January 2022 and June 2023, were randomly assigned to either a control group or an observation group, each comprising 60 individuals. The control group received conventional symptomatic treatments, including anti-infection and anti-cough therapies, while the observation group was additionally administered inhaled ambroxol hydrochloride via nebulization. We systematically compared the total clinical effective rate, symptom resolution time, pulmonary function indicators, and inflammatory factor levels before and after treatment. The results demonstrated that the observation group achieved a significantly higher total clinical effective rate (95.00%) compared to the control group (81.67%) (P < 0.05). Furthermore, the time required for the disappearance of cough, expectoration, and pulmonary rales was notably shorter in the observation group. Post-treatment evaluations revealed that pulmonary function metrics (FEV1, FVC, and FEV1/FVC) improved significantly more in the observation group. Concurrently, serum inflammatory markers, including hs-CRP, PCT, and IL-6, exhibited a more substantial decrease in the observation group than in the control group (P < 0.05). Importantly, the incidence of adverse reactions showed no statistically significant difference between the two cohorts. In conclusion, utilizing inhaled ambroxol hydrochloride as an adjunctive therapy for adult bacterial pneumonia significantly enhances clinical outcomes, accelerates symptom alleviation, improves pulmonary function, and effectively mitigates inflammatory responses while maintaining a highly favorable safety profile.
Keywords
References
[1] Z. Cyske, E. Rintz, L. Gaffke, K. Pierzynowska, and G. Węgrzyn, "The use of genistein and ambroxol may be an effective approach in correcting cellular dysfunctions of mucopolysaccharidosis-plus syndrome," Mammalian Genome, vol. 37, no. 1, p. 7, 2026.
[2] A. Kantar, L. Cavalieri, and G. Siscaro, "Ambroxol: mechanisms of action and efficacy for inhaled therapy in the treatment of respiratory diseases," Recenti Progressi in Medicina, vol. 116, no. 11 Suppl. 1, pp. 1–11, 2025.
[3] C. Li, Z. Chen, J. Shi, and X. Zheng, "Efficacy of ambroxol combined with loquat syrup on bacterial pneumonia in mice," Journal of Inflammation Research, pp. 10107–10117, 2024.
[4] X. Zhang, X. Zhang, J. Gu, L. Zhang, and R. Yang, "The efficacy of nebulized budesonide and ambroxol hydrochloride in treating pediatric community-acquired pneumonia and their impact on clinical characteristics and inflammatory markers," Journal of Health, Population and Nutrition, vol. 43, no. 1, p. 132, 2024.
[5] H. Shen, X. Zhao, and L. Xu, "Meta-analysis of the efficacy of budesonide and ambroxol hydrochloride inhalation in children with pneumonia and their effects on inflammatory response," Heliyon, vol. 9, no. 11, 2023.
[6] D. Wang, S. Sun, and S. Hu, "The therapeutic efficacy of high-dose ambroxol and the nursing effects in the treatment of severe pneumonia," Pakistan Journal of Pharmaceutical Sciences, vol. 32, 2019.
[7] V. Deretic and G. S. Timmins, "Enhancement of lung levels of antibiotics by ambroxol and bromhexine," Expert Opinion on Drug Metabolism & Toxicology, vol. 15, no. 3, pp. 213–218, 2019.
[8] M. Cataldi, V. Sblendorio, A. Leo, and O. Piazza, "Biofilm-dependent airway infections: a role for ambroxol?," Pulmonary Pharmacology & Therapeutics, vol. 28, no. 2, pp. 98–108, 2014.
[9] X. Gao, Y. Huang, Y. Han, C. X. Bai, and G. Wang, "The protective effects of Ambroxol in Pseudomonas aeruginosa-induced pneumonia in rats," Archives of Medical Science, vol. 7, no. 3, pp. 405–413, 2011.
[10] L. Chen and Y. Lv, "Efficacy and Safety Evaluation of Ambroxol Hydrochloride in Older Patients with Pneumonia Complicated with Heart Failure," Journal of Pharmaceutical Innovation, vol. 21, no. 2, p. 199, 2026.
[11] A. Xue, H. Zhang, S. Song, and X. Yu, "Effects of N-Acetylcysteine combined with Ambroxol Hydrochloride on clinical symptoms, CRP, and PCT in children with pneumonia," Clinics, vol. 79, p. 100476, 2024.
[12] F. Li, W. Wang, L. Hu, L. Li, and J. Yu, "Effect of ambroxol on ambroxol caused by Pseudomonas aeruginosa with biofilm formation in an endotracheal intubation rat model," Chemotherapy, vol. 57, no. 2, pp. 173–180, 2011.
[13] M. Cui, "Clinical Efficacy of Ambroxol Hydrochloride Injection and Cefotaxime Sodium Injection in the Treatment of Children with Bacterial Pneumonia," International Journal of Clinical and Experimental Medicine Research, vol. 9, no. 6, 2025.
Copyright and License
Published in2026-07-18 16:49:58
DOI https://doi.org/10.70088/3vnrre59
Creative Commons
Copyright: © 2026 by the authors.
Submitted for possible open access
publication under the terms and
conditions of the Creative Commons
Attribution (CC BY) license
(https://creativecommons.org/license
s/by/4.0/).
Copyright
Copyright © The Author(s), 2026. Published by SEMBE 2026
Journal Information
- Vol. 28 (2026): 2026 2nd International Conference on Agricultural Sciences, Economics, Biomedical and Environmental Sciences (SEMBE 2026)
- 2026-07-18
- ISSN: (Print) 3078-770X/ (Online) 3078-7718
- Journal Homepage